Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,280 | 156 | 98.1% |
| Education | $43.00 | 2 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $396.84 | 26 | $0 (2020) |
| PFIZER INC. | $391.38 | 32 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $295.40 | 15 | $0 (2019) |
| Supernus Pharmaceuticals, Inc. | $226.06 | 12 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $148.18 | 9 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $116.54 | 6 | $0 (2020) |
| Takeda Pharmaceuticals America, Inc. | $96.38 | 15 | $0 (2017) |
| Amgen Inc. | $87.81 | 5 | $0 (2018) |
| ABBVIE INC. | $55.10 | 3 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $53.30 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $19.87 | 1 | ABBVIE INC. ($19.87) |
| 2021 | $59.05 | 4 | AbbVie Inc. ($35.23) |
| 2020 | $193.13 | 13 | PFIZER INC. ($53.64) |
| 2019 | $506.66 | 39 | PFIZER INC. ($109.53) |
| 2018 | $650.78 | 36 | AstraZeneca Pharmaceuticals LP ($129.62) |
| 2017 | $893.21 | 65 | Allergan Inc. ($183.73) |
All Payment Transactions
158 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/29/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: Gastroenterology | ||||||
| 06/29/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: Gastroenterology | ||||||
| 06/21/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: NEUROSCIENCE | ||||||
| 04/14/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/29/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $15.89 | General |
| Category: Central Nervous System | ||||||
| 09/24/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: Diabetes | ||||||
| 09/22/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: NEUROSCIENCE | ||||||
| 08/24/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/11/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2020 | PFIZER INC. | CHANTIX (Drug), COLOGUARD | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 07/28/2020 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/21/2020 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $21.50 | General |
| Category: AED | ||||||
| 03/10/2020 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/26/2020 | PFIZER INC. | PREVNAR 13 (Biological) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: VACCINES | ||||||
| 01/23/2020 | SANOFI PASTEUR INC. | FLUZONE HIGH-DOSE (Biological), FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, PENTACEL | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: Vaccines | ||||||
| 01/07/2020 | PFIZER INC. | CHANTIX (Drug), COLOGUARD | Food and Beverage | In-kind items and services | $11.11 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 12/19/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/04/2019 | PFIZER INC. | CHANTIX (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 12/03/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.03 | General |
| Category: AED | ||||||
| 11/19/2019 | PFIZER INC. | CHANTIX (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $5.42 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 11/06/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $18.61 | General |
| Category: AED | ||||||
| 11/04/2019 | SANOFI-AVENTIS U.S. LLC | TOUJEO (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 1,470 | 1,916 | $471,993 | $154,345 |
| 2022 | 20 | 1,197 | 1,513 | $391,550 | $133,156 |
| 2021 | 18 | 1,122 | 1,381 | $370,130 | $126,124 |
| 2020 | 16 | 906 | 1,234 | $252,181 | $85,529 |
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 341 | 341 | $107,756 | $47,157 | 43.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 245 | 406 | $143,318 | $37,350 | 26.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 54 | 54 | $35,748 | $15,155 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 144 | 201 | $50,049 | $12,378 | 24.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 172 | 172 | $26,660 | $6,752 | 25.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 76 | 76 | $12,464 | $5,436 | 43.6% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 22 | 27 | $13,662 | $4,568 | 33.4% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 25 | 25 | $10,869 | $4,400 | 40.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 29 | $10,353 | $2,782 | 26.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 43 | $8,127 | $2,733 | 33.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 83 | 83 | $5,727 | $2,731 | 47.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 24 | 25 | $7,433 | $2,372 | 31.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 21 | 23 | $7,688 | $2,108 | 27.4% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 11 | 11 | $4,946 | $1,932 | 39.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 25 | 29 | $6,826 | $1,606 | 23.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 46 | 46 | $3,174 | $1,513 | 47.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 110 | $7,590 | $1,267 | 16.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 18 | 22 | $4,730 | $1,107 | 23.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 50 | 51 | $3,407 | $598.08 | 17.6% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 15 | 21 | $546.00 | $167.81 | 30.7% |
| 69209 | Removal of impacted ear wax by washing | Office | 2023 | 12 | 13 | $607.00 | $156.22 | 25.7% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 18 | 108 | $313.20 | $78.13 | 24.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 294 | 294 | $92,904 | $41,941 | 45.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 219 | 359 | $126,727 | $35,290 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 156 | 189 | $47,061 | $12,176 | 25.9% |
About Dr. Miguel Loya, D.O
Dr. Miguel Loya, D.O is a Internal Medicine healthcare provider based in Solvang, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2010. The National Provider Identifier (NPI) number assigned to this provider is 1619281532.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Miguel Loya, D.O has received a total of $2,323 in payments from pharmaceutical and medical device companies, with $19.87 received in 2022. These payments were reported across 158 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($2,280).
As a Medicare-enrolled provider, Loya has provided services to 4,695 Medicare beneficiaries, totaling 6,044 services with total Medicare billing of $499,153. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Solvang, CA
- Active Since 08/03/2010
- Last Updated 03/28/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1619281532
Products in Payments
- TROKENDI XR (Drug) $210.65
- ELIQUIS (Drug) $188.17
- BEVESPI AEROSPHERE (Drug) $177.31
- VRAYLAR (Drug) $144.28
- FARXIGA (Drug) $107.36
- BYSTOLIC (Drug) $75.72
- Trintellix (Drug) $72.28
- JARDIANCE (Drug) $70.84
- Prolia (Biological) $70.18
- XARELTO (Drug) $70.02
- UBRELVY (Drug) $69.39
- LYRICA (Drug) $62.01
- LINZESS (Drug) $57.82
- CHANTIX (Drug) $52.21
- PRADAXA (Drug) $51.44
- VIAGRA (Drug) $51.35
- XIFAXAN (Drug) $47.26
- INVOKANA (Drug) $46.52
- LONHALA MAGNAIR (Drug) $45.06
- BYVALSON (Drug) $37.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Solvang
Mrs. Kathryn Brewer, Md, MD
Internal Medicine — Payments: $4,278
Roger Lane, Md, MD
Internal Medicine — Payments: $3,221
Kim Peters, Md, MD
Internal Medicine — Payments: $1,997
Dr. Gustavo Dascanio, Md, MD
Internal Medicine — Payments: $748.16
William Heringer, Md, MD
Internal Medicine — Payments: $575.11
Lisa Clement, M.d, M.D
Internal Medicine — Payments: $95.85